USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
1 - 54 . (canceled)
55 . A method of treating chronic lymphocytic leukemia in a human subject comprising administering an anti-CD23 antibody, an anti-CD20 antibody, and at least one chemotherapeutic agent, wherein the anti-CD23 antibody, the anti-CD20 antibody, and the at least one chemotherapeutic agent are administered simultaneously or sequentially in any order.
56 . The method of claim 55 , wherein the anti-CD23 antibody is a human, humanized, or chimeric antibody.
57 . The method of claim 56 , wherein the anti-CD23 antibody comprises a human gamma 1 heavy chain constant region.
58 . The method of claim 56 , wherein the anti-CD23 antibody comprises a human kappa light chain constant region.
59 . The method of claim 56 , wherein the anti-CD23 antibody comprises variable regions of antibody 5E8.
60 . The method of claim 59 , wherein the anti-CD23 antibody comprises human constant regions.
61 . The method of claim 60 , wherein the anti-CD23 antibody is IDEC-152.
62 . The method of claim 55 , wherein the anti-CD23 antibody induces antibody-dependent cell-mediated cytotoxicity (ADCC) of chronic lymphocytic leukemia cells.
63 . The method of claim 55 , wherein the anti-CD23 antibody induces apoptosis of chronic lymphocytic leukemia cells.
64 . The method of claim 55 , wherein the anti-CD23 antibody is capable of inhibiting the binding to CD23 of a monoclonal antibody having light chain and heavy chain variable domains of antibody 5E8.
65 . The method of claim 64 , wherein the anti-CD23 antibody comprises human constant regions.
66 . The method of claim 64 , wherein the anti-CD23 antibody induces antibody-dependent cell-mediated cytotoxicity (ADCC) of chronic lymphocytic leukemia cells.
67 . The method of claim 64 , wherein the anti-CD23 antibody induces apoptosis of chronic lymphocytic leukemia cells.
68 . The method of claim 55 , wherein the anti-CD20 antibody induces antibody-dependent cell-mediated cytotoxicity (ADCC) of chronic lymphocytic leukemia cells.
69 . The method of claim 55 , wherein the anti-CD20 antibody induces apoptosis of chronic lymphocytic leukemia cells.
70 . The method of claim 68 , wherein the anti-CD20 antibody is rituximab.
71 . The method of claim 55 , wherein the at least one chemotherapeutic agent is fludarabine.
72 . The method of claim 55 , wherein the at least one chemotherapeutic agent is cyclophosphamide.
73 . The method of claim 55 , wherein the at least one chemotherapeutic agent is chlorambucil.
74 . A method of treating chronic lymphocytic leukemia in a human subject comprising administering an anti-CD23 antibody, an anti-CD20 antibody and at least one chemotherapeutic agent, wherein the anti-CD23 antibody is IDEC-152, wherein the anti-CD20 antibody is rituximab, wherein the at least one chemotherapeutic agent is fludarabine and wherein the anti-CD23 antibody, the anti-CD20 antibody and the at least one chemotherapeutic agent are administered simultaneously or sequentially in any order.